RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling
Cancer Letters · 2026-10 · 657 · 218580
DOI: 10.1016/j.canlet.2026.218580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-10. Verfasst von Wenpeng Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: .Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scie…. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Macrophage Colony-Stimulating Factor, DNA-Binding Proteins, Cell Cycle Proteins. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, primary and acquired resistance, driven largely by tumor cell-mediated remodeling of the immunosuppressive tumor microenvironment (TME), limits durable responses in most patients. The cohesin subunit RAD21 exhibits frequent copy number variation (CNV) across human cancers, yet its role in modulating tumor immunity remains poorly defined. Here, we identify RAD21 as a frequently amplified oncogene that promotes tumor cell proliferation and metastasis and whose elevated expression correlates with poor patient survival. Mechanistically, RAD21 drives M2 polarization of tumor-associated macrophages (TAMs) via upregulation of CSF1 signaling, thereby fostering an immunologically "cold" tumor and conferring resistance to anti-PD-1 therapy. RAD21 depletion reverses this immunosuppressive phenotype and, when combined with anti-PD-1 blockade, achieves maximal tumor regression. Our findings unveil a previously unrecognized oncogenic mechanism wherein RAD21 orchestrates immune evasion through activation of the CSF1 signaling and position RAD21 as a promising therapeutic target to overcome resistance to anti-PD-1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- .Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electro…
- .Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. E…
- .Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; .Depart…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Cai, W., Xiao, C., Xin, Y., Wang, D., Deng, Z., Liu, Y., Li, J., Liao, T., Yin, H., Li, C., & He, J. (2026). RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling. Cancer Letters, 657, 218580. https://doi.org/10.1016/j.canlet.2026.218580
Vancouver
Cai W, Xiao C, Xin Y, Wang D, Deng Z, Liu Y, et al. RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling. Cancer Letters. 2026;657:218580. doi:10.1016/j.canlet.2026.218580
BibTeX
@article{Cai2026,
author = {Cai, Wenpeng and Xiao, Chu and Xin, Ying and Wang, Di and Deng, Ziqin and Liu, Yixiao and Li, Jia and Liao, Tianle and Yin, Hongfei and Li, Chunxiang and He, Jie},
title = {RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling},
journal = {Cancer Letters},
year = {2026},
volume = {657},
pages = {218580},
doi = {10.1016/j.canlet.2026.218580}
}
EUVIMED